SELLAS Life Sciences Group, Inc. $SLS is Dagco Inc.'s 10th Largest Position

Key Points

• Dagco Inc. increased its SELLAS Life Sciences position by 19.8% in the second quarter, holding 1.23 million shares worth approximately $18.2 million. Institutional investors collectively own 17.38% of SLS.
• Analyst views remain mixed, with two Buy ratings and one Sell rating producing a consensus Hold rating and a $10.00 price target.
• SLS shares opened at $11.05, compared with a one-year range of $1.39 to $15.88. The company reported a quarterly loss of $0.05 per share, missing the $0.04 consensus estimate.

Dagco Inc. increased its position in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) by 19.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,232,433 shares of the company's stock after buying an additional 203,653 shares during the period. SELLAS Life Sciences Group accounts for 3.4% of Dagco Inc.'s holdings, making the stock its 10th biggest position. Dagco Inc. owned about 0.63% of SELLAS Life Sciences Group worth $18,191,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SLS. Larson Financial Group LLC acquired a new position in shares of SELLAS Life Sciences Group in the fourth quarter worth about $26,000. BNP Paribas Financial Markets grew its position in shares of SELLAS Life Sciences Group by 89.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company's stock valued at $32,000 after acquiring an additional 9,299 shares during the period. Concurrent Investment Advisors LLC purchased a new position in shares of SELLAS Life Sciences Group in the 4th quarter valued at about $38,000. Beacon Pointe Advisors LLC purchased a new position in shares of SELLAS Life Sciences Group in the 4th quarter valued at about $38,000. Finally, California State Teachers Retirement System raised its holdings in SELLAS Life Sciences Group by 22.4% in the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company's stock worth $39,000 after purchasing an additional 1,709 shares during the period. Hedge funds and other institutional investors own 17.38% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a report on Friday, July 17th. Alliance Global Partners reaffirmed a "buy" rating on shares of SELLAS Life Sciences Group in a research note on Monday, July 6th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $10.00.

SELLAS Life Sciences Group Stock Performance

Shares of SELLAS Life Sciences Group stock opened at $11.05 on Wednesday. The business's 50 day moving average price is $11.01 and its 200 day moving average price is $7.24. The company has a market cap of $2.17 billion, a price-to-earnings ratio of -48.04 and a beta of 2.48. SELLAS Life Sciences Group, Inc. has a one year low of $1.39 and a one year high of $15.88.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.

The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source